SurgPASS is a pilot randomised cluster trial utilising a pre-operative checklist with the aim of reducing deaths after surgery. If SurgPASS is successful, the intervention will be implemented in a separate full-scale cluster randomised trial.

开始日期2025-06-01

申办/合作机构

University of Birmingham

[+3]

CTRI/2025/04/085308

/ Not yet recruiting临床4期IIT

TO STUDY THE CLINICAL RESPONSE AND SAFETY OF ANGIOTENSIN RECEPTOR- NEPRILYSIN INHIBITOR (SACUBITRIL/ VALSARTAN) IN PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE AND HEART FAILURE WITH REDUCED EJECTION FRACTION - Nil

开始日期2025-05-02

申办/合作机构

Christian Medical College & Hospital

CTRI/2025/03/083693

/ Not yet recruiting临床4期IIT

Comparison of clinical performance and hemodynamic changes of two supraglottic airway devices, I-gel with proseal - laryngeal mask airway(LMA) in patients undergoing elective surgeries A prospective randomized study - CLIP Study-Comparison of Laryngeal mask airway (ProSeal) and I-gel in Patients undergoing elective surgeries with Laryngeal Management.

开始日期2025-04-19

申办/合作机构

Christian Medical College & Hospital

100 项与 Christian Medical College & Hospital 相关的临床结果

登录后查看更多信息

0 项与 Christian Medical College & Hospital 相关的专利（医药）

登录后查看更多信息

8,785

项与 Christian Medical College & Hospital 相关的文献（医药）

2025-05-01·Clinical Microbiology and Infection

Re: ‘Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward’ by tängdén et al.

Letter

作者: Veeraraghavan, Balaji ; Egli, Adrian ; Walia, Kamini

A polemic in response to tangden et al on introducing new antibiotics for multidrug-resistant bacteria.The authors highlighted the limited clin. evidence available for novel antibiotics at the time of approval.The authors argue that registrational trials often exclude patients with multidrug-resistant infections or are limited in size.Although this observation is accurate, conducting large trials in such populations is fraught with challenges, including high screen failure rates, complex diagnostic requirements, and exorbitant costs.These trials necessitate enrolling patients with specific resistance patterns, which are often geog. concentrated in high-resistance regions such as Asia and Eastern Europe.The authors criticize the choice of comparators in registrational trials, stating they do not reflect real-world standard-of-care (SOC).The authors raise ethical concerns regarding the lack of sitelevel antibiotic susceptibility testing in trials, arguing it impedes de-escalation of therapy.In conclusion, although the challenges of developing and approving novel antibiotics are undeniable, the regulatory and operational frameworks in place have enabled critical progress in the fight against multidrug-resistant pathogens.Thus the author concluded rather than criticizing fast-track approvals and smaller trials, efforts should focus on supporting developers through global collaboration, financial incentives, and capacity building in low-and-middle-income countries.

2025-04-01·Clinical Microbiology and Infection

Re: ‘Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates’ by Poirel et al.

Letter

作者: Veeraraghavan, Balaji ; Egli, Adrian ; Walia, Kamini

A review.In this study, the authors examined the standalone antibacterial activity of durlobactam, a diazabicyclooctane (DBO) b-lactamase inhibitor, and the sulbactam/durlobacatam combination against E. coli isolates harbouring New Delhi metallo-b-lactamase (NDM) and amino acid insertions in the penicillin-binding-protein 3 (PBP3).Recently, the sulbactam/durlobactam combination has been approved in the United States to treat infections caused by carbapenem-resistant Acinetobacter baumannii.The authors suggest that this combination might also serve as an alternative therapy for patients with infections caused by NDM-producing E. coli isolates, harbouring insertions in PBP3, particularly those resistant to aztreonam/avibactam and cefiderocol.Although the authors recommended further PK/PD and clin. evaluations, their conclusion solely based on the study of minimal inhibitory concentrations is unfounded.Moreover, the methodol. employed to determine the activity of the sulbactam/durlobactam is inappropriate because durlobactam was used at a fixed concentration of 4mg/mL, at which the durlobactam showed standalone antibacterial activity.

2025-04-01·APIK Journal of Internal Medicine

A Cross-sectional Study of Prevalence of Adrenal Insufficiency in Patients with Primary Autoimmune Hypothyroidism in a Tertiary Hospital, India

作者: Jacob, Jubbin Jagan ; Singh, Navjot ; Saini, Paramjit Kaur

AbstractObjectives:This study aimed to assess the prevalence of adrenal insufficiency in patients with primary hypothyroidism who continued to be symptomatic despite adequate biochemical correction of hypothyroidism with synthetic levothyroxine.Methods:This cross-sectional study included 160 patients aged 18–70 years and with primary autoimmune hypothyroidism (PAH) for at least 3 months with normal thyroid-stimulating hormone values. Anti-thyroid peroxidase levels, basal cortisol levels, and 60-min postadrenocorticotropic hormone test were done in the 20 patients who continued to be symptomatic on the Zulevski scale despite euthyroid levels. The comparison of various demographic and clinical factors was done with adrenal insufficiency. P <0.05 was considered statistically significant.Results:Among 20 symptomatic AIT patients, 8 (40%) were found to have adrenal insufficiency. There was no statistical difference in the age, gender, body mass index, and duration of disease with adrenal insufficiency (P > 0.05). The mean dose of L-thyroxine with adrenal insufficiency and those without adrenal insufficiency were comparable and the difference was not statistically significant (62.5 vs. 68.75 P = 0.4).Conclusions:Adrenal insufficiency may be present in patients with hypothyroidism who continue to be symptomatic despite euthyroid levels. The investigations in such patients must not be restricted to just thyroid monitoring but must extend to adrenal function assessment to rule out polyglandular involvement.

100 项与 Christian Medical College & Hospital 相关的药物交易

登录后查看更多信息

100 项与 Christian Medical College & Hospital 相关的转化医学

登录后查看更多信息